(Q34778360)

4 August 2017

title

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis (English)

1 reference

4 August 2017

1 reference

R-M Szeimies

1

1 reference

4 August 2017

J Bichel

2

1 reference

4 August 2017

J-P Ortonne

3

1 reference

4 August 2017

E Stockfleth

4

1 reference

4 August 2017

J Lee

5

1 reference

4 August 2017

T-C Meng

6

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2008

1 reference

British Journal of Dermatology

4 August 2017

published in

1 reference

4 August 2017

volume

159

1 reference

4 August 2017

issue

1

1 reference

4 August 2017

page(s)

205-210

1 reference

Premalignant keratinocytic neoplasms

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis").

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Gene expression in actinic keratoses: pharmacological modulation by imiquimod.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2008.08615.X

10.1111/J.1365-2133.2008.08615.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference